The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
Open accessAbstract
Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of epileptic seizures, about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Patients with such drug-resistant epilepsy (DRE) have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life, so development of more effective therapies is an urgent clinical need. However, the various types of epilepsy and seizures and the complex temporal patterns of refractoriness complicate the issue. Furthermore, the underlying mechanisms of DRE are not fully understood, though recent work has begun to shape our understanding more clearly. Experimental models of DRE offer opportunities to discover, characterize, and challenge putative mechanisms of drug resistance. Furthermore, such preclinical models are important in developing therapies that may overcome drug resistance. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of ASD resistance and discuss how to overcome this problem. Encouragingly, better elucidation of the pathophysiological mechanisms underpinning epilepsies and drug resistance by concerted preclinical and clinical efforts have recently enabled a revised approach to the development of more promising therapies, including numerous potential etiology-specific drugs ("precision medicine") for severe pediatric (monogenetic) epilepsies and novel multitargeted ASDs for acquired partial epilepsies, suggesting that the long hoped-for breakthrough in therapy for as-yet ASD-resistant patients is a feasible goal. SIGNIFICANCE STATEMENT: Drug resistance provides a major challenge in epilepsy management. Here, we will review the current understanding of the molecular, genetic, and structural mechanisms of drug resistance in epilepsy and discuss how the problem might be overcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–238 of 238
Novel therapies for epilepsy in the pipeline
Mesraoua, B., Deleu, D., Kullmann, D. M., Shetty, A. K., Boon, P., Perucca, E., Mikati, M. A., & Asadi‐Pooya, A. A. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.042 · Cited by 50
Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide
Brodie, M. J. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0678-x · Cited by 49
ABCB1 Genotyping in the Treatment of Depression
Brückl, T. M., & Uhr, M. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.18 · Cited by 49
Neuroinflammation Alters Integrative Properties of Rat Hippocampal Pyramidal Cells
Frigerio, F., Flynn, C., Han, Y. S., Lyman, K. A., Lugo, J. N., Ravizza, T., Ghestem, A., Pitsch, J., Becker, A. J., Anderson, A. E., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0915-1 · Cited by 49
Self-citationLeclercq, K., Matagne, A., Provins, L., Klitgaard, H., & Kaminski, R. M. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261222 · Cited by 48
Töllner, K., Wolf, S., Löscher, W., & Gernert, M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2506-11.2011 · Cited by 46
Self-citationLeclercq, K., Afrikanova, T., Langlois, M., Prins, A. D., Buenafe, O. E. M., Rospo, C. C., Eeckhaut, A. V., de Witte, P. A. M., Crawford, A. D., Smolders, I. J., et al. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.03.019 · Cited by 45
Dynamic Regulation of P-glycoprotein in Human Brain Capillaries
Avemary, J., Salvamoser, J. D., Peraud, A., Rémi, J., Noachtar, S., Fricker, G., & Potschka, H. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4001102 · Cited by 45
Self-citationWengert, E. R., Saga, A. U., Panchal, P. S., Barker, B. S., & Patel, M. K. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107699 · Cited by 45
Wood, M. D., Daniëls, V., Provins, L., Wolff, C., Kaminski, R. M., & Gillard, M. R. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261149 · Cited by 45
Bankstahl, M., Bankstahl, J. P., & Löscher, W. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.09.014 · Cited by 44
Self-citationAdjunctive use of verapamil in patients with refractory temporal lobe epilepsy: A pilot study
Asadi‐Pooya, A. A., Razavizadegan, S. M. A., Abdi‐Ardekani, A., & Sperling, M. R. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.07.006 · Cited by 43
Xu, Z., Wang, Y., Tao, A., Yu, J., Wang, X., Zu, Y., Zhang, S., & Chen, Z. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.04.036 · Cited by 42
Polster, T. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.021 · Cited by 41
Using Patient-Derived Induced Pluripotent Stem Cells to Model and Treat Epilepsies
Du, X., & Parent, J. M. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0588-3 · Cited by 39
Deng, X., Shao, Y., Xie, Y., Feng, Y., Wu, M., Wang, M., & Chen, Y. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00937 · Cited by 39
A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures
Borlot, F., Wither, R. G., Ali, A., Wu, N., Verocai, F., & Andrade, D. M. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.08.009 · Cited by 37
Current Treatment Strategies and Future Treatment Options for Dravet Syndrome
Ziobro, J. M., Eschbach, K. L., Sullivan, J. E., & Knupp, K. G. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0537-y · Cited by 37
Rojas, A., Gueorguieva, P., Lelutiu, N. B., Quan, Y., Shaw, R. N., & Dingledine, R. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.004 · Cited by 36
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
Bertoni, C., & Namgoong, J. (2016) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s71808 · Cited by 34
Metcalf, C. S., Huff, J. L., Thomson, K. E., Johnson, K. J., Edwards, S. F., & Wilcox, K. S. (2019) · Epilepsia Open · doi:10.1002/epi4.12354 · Cited by 34
Narayanan, J., Frech, R., Walters, S., Patel, V. A., Frigerio, R., & Maraganore, D. M. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.07.004 · Cited by 32
Frederiksen, K., Lu, D., Yang, J., Jensen, H. S., Bastlund, J. F., Larsen, P. H., Liu, H., Crestey, F., Dekermendjian, K., Badolo, L., et al. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13626 · Cited by 31
West, P. J., Saunders, G. W., Billingsley, P., Smith, M. D., White, H. S., Metcalf, C. S., & Wilcox, K. S. (2018) · Epilepsia · doi:10.1111/epi.14563 · Cited by 30
What New Modeling Approaches Will Help Us Identify Promising Drug Treatments?
Baraban, S. C., & Löscher, W. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-8914-1_23 · Cited by 29
Self-citationMechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery
Margineanu, D. G., & Klitgaard, H. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460440802611729 · Cited by 28
Emerging drugs for the treatment of Dravet syndrome
Brigo, F., Striano, P., Balagura, G., & Belcastro, V. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1552937 · Cited by 28
miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model
Haenisch, S., von Rüden, E., Wahmkow, H., Rettenbeck, M. L., Michler, C., Russmann, V., Bruckmueller, H., Waetzig, V., Cascorbi, I., & Potschka, H. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00222 · Cited by 27
Self-citationPorter, R. J., & Kupferberg, H. J. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2215-y · Cited by 27
Mechanisms of Drug Resistance in Epilepsy: Lessons from Oncology
Binder, D. K. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02441-8 · Cited by 25
Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy
Orlandi, A., Paolino, M. C., Striano, P., & Parisi, P. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1473377 · Cited by 24
Stem cells: A path towards improved epilepsy therapies
Lybrand, Z. R., Goswami, S., & Hsieh, J. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107781 · Cited by 23
Heterogeneous GABAA receptor subunit expression in pediatric epilepsy patients
Porter, B. E., Zhang, G., Celix, J. M., Hsu, F., Raol, Y. H., Telfeian, A. E., Gallagher, P. R., Coulter, D. A., & Brooks‐Kayal, A. R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.010 · Cited by 17
Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?
Zaccara, G., Mula, M., Ferrò, B., Consoli, D., Elia, M., Giallonardo, A. T., Iudice, A., Neve, A. L., Meletti, S., Tinuper, P., et al. (2018) · Epilepsia · doi:10.1111/epi.14622 · Cited by 16
Leclercq, K., & Kaminski, R. M. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.06.011 · Cited by 15
Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives
Gambardella, A., Labate, A., Mumoli, L., Lopes‐Cendes, Í., & Cendes, F. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170911111536 · Cited by 14
Epilepsy genetics and the precision medicine matrix
Sisodiya, S. M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30331-x · Cited by 10
Self-citationMechanisms of Drug Resistance and Tolerance
Shorvon, W. L., & Schmidt, D. (2015) · Wiley eBooks · doi:10.1002/9781118936979.ch7 · Cited by 3
Cited by
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
Self-citationPerucca, E., Perucca, P., White, H. S., & Wirrell, E. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00151-5 · Cited by 305
Astrocytes in the initiation and progression of epilepsy
Vezzani, A., Ravizza, T., Bedner, P., Aronica, E., Steinhäuser, C., & Boison, D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00727-5 · Cited by 272
Self-citationThe Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.674483 · Cited by 269
Asadi-Pooya, A. A., Brigo, F., Lattanzi, S., & Blumcke, I. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01048-6 · Cited by 265
Metadata
- Authors
- Löscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 72
- Issue
- 3
- Pages
- 606-638
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W3035511928
- Cited by
- 903
- References
- 238
- FWCI
- 58.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.